Autopsy report · NCT03395873
Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy
Cause of deathRegulatory or ethics
“Recent FDA approval of a new drug for the same patient population”
Life of this trial
- Registered 1 month before it started.
- Ran for about 1 year 4 months before it stopped.
- 7 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Milton S. Hershey Medical Center
- Sponsor type
- University, hospital or other
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Avelumab
- Participants
- 7
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer
“Study Drug was FDA approved Summer 2021” - Perceval S Aortic Heart Valve Study- North America
“FDA approval” - BreathID Multi-center HCV Liver Breath Test Study
“Due to FDA comments, protocol changed; new trial will be proposed shortly” - An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
“Trial has been cancelled due to availability of new therapeutic options for patient population” - The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine
“Pending FDA approval”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.